Alvotech S.A (ALVO) | Financial Analysis & Statements
Alvotech S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
166.6M
Gross Profit
105.3M
63.21%
Operating Income
48.3M
28.97%
Net Income
-108.5M
-65.16%
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
1.8B
Shareholders Equity
-284.5M
Cash Flow Metrics
Operating Cash Flow
-35.8M
Free Cash Flow
-78.7M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Alvotech S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 586.3M | 489.7M | 91.4M | 83.0M | 36.8M |
| Cost of Goods Sold | 235.6M | 185.3M | 160.9M | 64.1M | 0 |
| Gross Profit | 350.8M | 304.4M | -69.4M | 18.9M | 36.8M |
| Gross Margin % | 59.8% | 62.2% | -75.9% | 22.8% | 100.0% |
| Operating Expenses | |||||
| Research & Development | 184.2M | 171.3M | 210.8M | 180.6M | 191.0M |
| Selling, General & Administrative | 84.9M | 61.5M | 76.6M | 186.7M | 84.1M |
| Other Operating Expenses | -2.6M | -2.3M | -1.9M | -2.0M | -2.9M |
| Total Operating Expenses | 266.5M | 230.5M | 285.4M | 365.4M | 272.2M |
| Operating Income | 78.2M | 69.6M | -354.9M | -346.4M | -235.5M |
| Operating Margin % | 13.3% | 14.2% | -388.1% | -417.3% | -640.3% |
| Non-Operating Items | |||||
| Interest Income | 2.8M | 4.6M | 4.8M | 912.0K | 19.0K |
| Interest Expense | 136.9M | 154.0M | 133.2M | 77.5M | 113.0M |
| Other Non-Operating Income | 201.5M | -134.2M | -166.2M | -114.7M | 200.8M |
| Pre-tax Income | 136.3M | -217.6M | -651.0M | -551.6M | -149.2M |
| Income Tax | 108.4M | 14.3M | -99.3M | -38.1M | -47.7M |
| Effective Tax Rate % | 79.5% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | 27.9M | -231.9M | -551.7M | -513.6M | -101.5M |
| Net Margin % | 4.8% | -47.3% | -603.4% | -618.6% | -276.0% |
| Key Metrics | |||||
| EBITDA | 109.6M | 101.9M | -334.6M | -341.7M | -221.2M |
| EPS (Basic) | $0.10 | $-0.87 | $-2.43 | $-2.60 | $-0.92 |
| EPS (Diluted) | $0.10 | $-0.87 | $-2.43 | $-2.60 | $-0.92 |
| Basic Shares Outstanding | 279190000 | 266510345 | 227256469 | 197530769 | 110673309 |
| Diluted Shares Outstanding | 279190000 | 266510345 | 227256469 | 197530769 | 110673309 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Alvotech S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 172.4M | 51.4M | 11.2M | 66.4M | 17.6M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 69.7M | 160.2M | 41.3M | 33.0M | 29.4M |
| Inventory | 220.1M | 127.9M | 74.4M | 71.5M | 39.1M |
| Other Current Assets | - | - | - | - | - |
| Total Current Assets | 574.0M | 455.0M | 194.8M | 230.7M | 119.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 6.6M | 124.9M | 119.4M | 47.2M | 126.6M |
| Goodwill | 107.5M | 43.3M | 43.2M | 48.9M | 46.2M |
| Intangible Assets | 81.8M | 20.6M | 19.1M | 25.7M | 21.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 323.7M | 324.7M | 349.0M | 243.7M | 183.6M |
| Total Non-Current Assets | 913.1M | 766.4M | 755.2M | 597.7M | 478.2M |
| Total Assets | 1.5B | 1.2B | 950.1M | 828.4M | 598.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 126.1M | 67.1M | 80.6M | 49.2M | 28.6M |
| Short-term Debt | 49.0M | 42.2M | 47.7M | 25.1M | 10.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 304.1M | 193.4M | 261.0M | 167.3M | 111.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.4B | 1.1B | 1.0B | 780.0M | 513.0M |
| Deferred Tax Liabilities | 7.9M | 1.8M | 53.0K | 309.0K | 150.0K |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 1.5B | 1.4B | 1.6B | 1.2B | 621.8M |
| Total Liabilities | 1.8B | 1.6B | 1.9B | 1.4B | 733.6M |
| Equity | |||||
| Common Stock | 2.9M | 2.8M | 2.3M | 2.1M | 135.0K |
| Retained Earnings | -2.4B | -2.4B | -2.2B | -1.7B | -1.1B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -284.5M | -412.8M | -932.5M | -564.4M | -135.6M |
| Key Metrics | |||||
| Total Debt | 1.4B | 1.2B | 1.1B | 805.1M | 523.1M |
| Working Capital | 269.9M | 261.6M | -66.1M | 63.4M | 8.0M |
Balance Sheet Composition
Alvotech S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 27.9M | -231.9M | -551.7M | -513.6M | -101.5M |
| Depreciation & Amortization | 37.9M | 31.3M | 24.2M | 20.4M | 18.2M |
| Stock-Based Compensation | 7.4M | 7.6M | 18.0M | 10.3M | 0 |
| Working Capital Changes | -163.0M | -274.9M | -5.4M | -64.3M | -6.8M |
| Operating Cash Flow | -48.4M | -161.2M | -484.2M | -378.5M | -157.1M |
| Investing Activities | |||||
| Capital Expenditures | -64.5M | -53.7M | -33.1M | -37.5M | -20.5M |
| Acquisitions | -8.1M | 12.0M | - | - | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -72.6M | -15.5M | -33.1M | -52.4M | -20.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 233.5M | 920.8M | 278.8M | 193.7M | 113.8M |
| Debt Repayment | -35.8M | -768.8M | -107.6M | -95.9M | -44.8M |
| Financing Cash Flow | 270.8M | 282.9M | 294.9M | 374.9M | 254.8M |
| Free Cash Flow | -146.3M | -293.8M | -358.7M | -361.4M | -268.8M |
| Net Change in Cash | 149.9M | 106.2M | -222.3M | -56.0M | 77.3M |
Cash Flow Trend
Alvotech S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
33.80
Forward P/E
18.47
Price to Sales
1.79
PEG Ratio
18.47
Profitability Ratios
Profit Margin
4.74%
Operating Margin
33.84%
Return on Equity
-9.81%
Return on Assets
3.82%
Financial Health
Current Ratio
1.89
Debt to Equity
-5.09
Beta
0.25
Per Share Data
EPS (TTM)
$0.10
Book Value per Share
$-0.91
Revenue per Share
$2.03
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALVO | 1.1B | 33.80 | - | -9.81% | 4.74% | -5.09 |
| Zoetis | 49.8B | 19.58 | 15.04 | 65.99% | 28.24% | 279.59 |
| Haleon Plc - ADR | 42.4B | 18.72 | 1.88 | 10.27% | 15.11% | 52.37 |
| Dynavax Technologies | 1.8B | 54.60 | 3.41 | -7.14% | -13.13% | 54.15 |
| Ani Pharmaceuticals | 1.8B | 24.08 | 3.10 | 16.16% | 8.87% | 116.19 |
| Perrigo Company plc | 1.6B | 2,818.00 | 0.55 | -38.66% | -33.51% | 131.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.






